Table 1

 Clinical features, antiretroviral therapy, and time interval between the first and second MRI study of the brain in six patients with HIV leucoencephalopathy

PatientAge/sexCD4 count (×106/l)Clinical presentationDrug treatmentTime interval to 2nd MRI and CD4 countBiopsy results
*Only patient 2 had neuropsychological testing at the time of clinical presentation and after the symptoms had improved; †only patient 5 had received AZT 600 mg/day for a period of 3 months before the onset of cognitive decline.
AZT, AZT, 3′-azido-3′-deoxythymidine; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; NK, not known; TNFα, tumour necrosis factor α.
131/M105Depression for 6 months, followed by confusion, falls, leg weakness for 3 monthsAZT 600 mg/day5 weeks/375
2*42/M80Failing memory, frequent falls for 3 monthsAZT 800 mg/day12 weeks/567
341/M160Memory problems for 4 monthsAZT 800 mg/day4 weeks/NK
440/M98Mental decline for 10 weeksAZT 1000 mg/day5 months/439Extensive TNFα, HLA-DR staining
5†46/M110Personality changes, memory difficulties for 2 monthsAZT 600 mg/day SaquinavirExtensive TNFα, HLA-DR staining
633/M<50Confusional state for 4 weeksAZT 600 mg/day D4T 60 mg/day5 weeks/170Necropsy: gp41, TNFα, HLA-DR staining